KR100895571B1 - 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진 - Google Patents

혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진 Download PDF

Info

Publication number
KR100895571B1
KR100895571B1 KR1020087021379A KR20087021379A KR100895571B1 KR 100895571 B1 KR100895571 B1 KR 100895571B1 KR 1020087021379 A KR1020087021379 A KR 1020087021379A KR 20087021379 A KR20087021379 A KR 20087021379A KR 100895571 B1 KR100895571 B1 KR 100895571B1
Authority
KR
South Korea
Prior art keywords
ring
alkyl
substituted
atoms
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020087021379A
Other languages
English (en)
Korean (ko)
Other versions
KR20080086547A (ko
Inventor
자크 피. 듀마스
테디 카이트 조
해롤드 씨. 이. 클루엔더
웬디 리
다나팔란 나가라쓰남
로버트 엔. 시블리
닝 수
스티븐 제임스 보이어
줄리 에이. 딕슨
Original Assignee
바이엘 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 코포레이션 filed Critical 바이엘 코포레이션
Publication of KR20080086547A publication Critical patent/KR20080086547A/ko
Application granted granted Critical
Publication of KR100895571B1 publication Critical patent/KR100895571B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
KR1020087021379A 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진 Expired - Lifetime KR100895571B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28
US09/407,600 1999-09-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020027003972A Division KR100890473B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진

Publications (2)

Publication Number Publication Date
KR20080086547A KR20080086547A (ko) 2008-09-25
KR100895571B1 true KR100895571B1 (ko) 2009-04-29

Family

ID=23612752

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020087021379A Expired - Lifetime KR100895571B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진
KR1020027003972A Expired - Lifetime KR100890473B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진
KR1020087021380A Expired - Lifetime KR100895572B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020027003972A Expired - Lifetime KR100890473B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진
KR1020087021380A Expired - Lifetime KR100895572B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진

Country Status (35)

Country Link
EP (1) EP1228063B1 (https=)
JP (1) JP4919567B2 (https=)
KR (3) KR100895571B1 (https=)
CN (3) CN100422173C (https=)
AR (3) AR025752A1 (https=)
AT (1) ATE422494T1 (https=)
AU (1) AU782820B2 (https=)
BG (1) BG65860B1 (https=)
BR (1) BRPI0014382B8 (https=)
CA (1) CA2385817C (https=)
CO (1) CO5200835A1 (https=)
CZ (1) CZ304767B6 (https=)
DE (1) DE60041548D1 (https=)
DO (1) DOP2000000070A (https=)
EE (1) EE05258B1 (https=)
ES (1) ES2320525T3 (https=)
GT (1) GT200000158A (https=)
HR (1) HRP20020308A2 (https=)
HU (1) HU230223B1 (https=)
IL (3) IL148880A0 (https=)
MA (1) MA25563A1 (https=)
MX (1) MXPA02003156A (https=)
MY (3) MY135058A (https=)
NO (1) NO20021520L (https=)
NZ (1) NZ518589A (https=)
PA (1) PA8503201A1 (https=)
PE (1) PE20010607A1 (https=)
PL (1) PL205957B1 (https=)
RS (1) RS50369B (https=)
RU (1) RU2260008C2 (https=)
SK (1) SK287417B6 (https=)
TW (1) TW593315B (https=)
UA (1) UA75053C2 (https=)
WO (1) WO2001023375A2 (https=)
ZA (1) ZA200202760B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416525A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
ATE421324T1 (de) * 2003-03-11 2009-02-15 Novartis Ag Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
JPWO2004089412A1 (ja) * 2003-04-08 2006-07-06 三菱ウェルファーマ株式会社 特異的ｎａｄ（ｐ）ｈオキシダーゼ抑制剤
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
EP2010173A1 (en) * 2006-04-15 2009-01-07 Bayer HealthCare AG Compounds for treating pulmonary hypertension
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA
US12421228B2 (en) * 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035958A1 (en) * 1997-02-13 1998-08-20 Novartis Ag Phthalazines with angiogenesis inhibiting activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
WO1996005176A1 (en) * 1994-08-09 1996-02-22 Eisai Co., Ltd. Fused pyridazine compound
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
ATE459616T1 (de) * 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
WO2000059509A1 (en) * 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035958A1 (en) * 1997-02-13 1998-08-20 Novartis Ag Phthalazines with angiogenesis inhibiting activity

Also Published As

Publication number Publication date
MY143580A (en) 2011-05-31
GT200000158A (es) 2002-03-16
HK1091818A1 (zh) 2007-01-26
IL193367A (en) 2011-03-31
KR100890473B1 (ko) 2009-03-26
AU1569601A (en) 2001-04-30
KR20080086547A (ko) 2008-09-25
KR20080091505A (ko) 2008-10-13
ES2320525T3 (es) 2009-05-25
PE20010607A1 (es) 2001-07-12
EE05258B1 (et) 2010-02-15
BRPI0014382B8 (pt) 2021-05-25
DOP2000000070A (es) 2002-02-28
CA2385817A1 (en) 2001-04-05
CA2385817C (en) 2010-05-04
EE200200161A (et) 2003-08-15
HRP20020308B1 (https=) 2013-01-31
KR20020038775A (ko) 2002-05-23
CN1769283A (zh) 2006-05-10
RU2260008C2 (ru) 2005-09-10
WO2001023375A3 (en) 2002-05-02
HRP20020308A2 (en) 2004-06-30
KR100895572B1 (ko) 2009-04-29
BR0014382B1 (pt) 2014-04-01
ATE422494T1 (de) 2009-02-15
AR025752A1 (es) 2002-12-11
YU22902A (sh) 2004-12-31
BG106637A (bg) 2003-02-28
WO2001023375A2 (en) 2001-04-05
NO20021520L (no) 2002-05-23
AU782820B2 (en) 2005-09-01
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
HUP0202704A3 (en) 2003-12-29
SK5912002A3 (en) 2003-01-09
MY143377A (en) 2011-05-13
DE60041548D1 (de) 2009-03-26
HK1091819A1 (zh) 2007-01-26
PA8503201A1 (es) 2002-08-26
CN100422172C (zh) 2008-10-01
AR082231A2 (es) 2012-11-21
MXPA02003156A (es) 2002-09-30
CN100422173C (zh) 2008-10-01
UA75053C2 (en) 2006-03-15
RS50369B (sr) 2009-11-10
IL148880A0 (en) 2002-09-12
BG65860B1 (bg) 2010-03-31
EP1228063B1 (en) 2009-02-11
CZ20021444A3 (cs) 2002-08-14
CN1420879A (zh) 2003-05-28
CO5200835A1 (es) 2002-09-27
HUP0202704A2 (hu) 2002-12-28
IL193368A0 (en) 2009-02-11
MA25563A1 (fr) 2002-10-01
HU230223B1 (en) 2015-10-28
PL205957B1 (pl) 2010-06-30
AR082232A2 (es) 2012-11-21
TW593315B (en) 2004-06-21
ZA200202760B (en) 2003-10-29
JP2003526632A (ja) 2003-09-09
BR0014382A (pt) 2003-06-24
NZ518589A (en) 2005-03-24
IL193367A0 (en) 2009-02-11
PL366342A1 (en) 2005-01-24
NO20021520D0 (no) 2002-03-26
CZ304767B6 (cs) 2014-10-08
MY135058A (en) 2008-01-31
SK287417B6 (sk) 2010-09-07
CN100374435C (zh) 2008-03-12
IL193368A (en) 2011-05-31
JP4919567B2 (ja) 2012-04-18

Similar Documents

Publication Publication Date Title
KR100895571B1 (ko) 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진
KR20020019969A (ko) 혈관신생 억제 활성을 갖는 치환 피리다진 및 융합 피리다진
US6689883B1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US20110263597A1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US8304406B2 (en) Compounds for treating pulmonary hypertension
HK1091818B (en) Substitued pyridines and pyridazines with angiogenesis inhibiting activity
HK1091819B (en) Substitued pyridines and pyridazines with angiogenesis inhibiting activity

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080901

Application number text: 1020027003972

Filing date: 20020327

PA0201 Request for examination
PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20090403

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090422

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090422

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20120405

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20120405

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130409

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130409

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20140408

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140408

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20150408

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150408

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160408

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160408

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20170412

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20170412

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180405

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180405

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20190410

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20190410

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20200416

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20200416

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term